Efficacy and Safety Equivalence of Proposed High-Concentration Adalimumab Biosimilar to Reference Adalimumab in Moderate-to-Severe, Active RA

2020 Year in Review - Biosimilars

A randomized, double-blind phase 3 study demonstrated the efficacy and safety equivalence of the adalimumab biosimilar candidate CT-P17 to reference adalimumab in patients with moderate-to-severe active rheumatoid arthritis (RA).

CT-P17 is a proposed biosimilar of the high-concentration (100 mg/mL) and citrate-free formulation of reference adalimumab. A randomized, double-blind phase 3 study was initiated to compare the efficacy and safety of CT-P17 with reference adalimumab in patients with active, moderate-to-severe rheumatoid arthritis (RA) up to week 52; study results were reported at the American College of Rheumatology (ACR) Convergence 2020 meeting.

Inclusion criteria were adult patients with active, moderate-to-severe RA despite methotrexate treatment. Eligible patients were randomized 1:1 to receive CT-P17 40 mg or reference adalimumab every 2 weeks up to week 24. Prior to dosing at week 26, patients in the reference adalimumab group were re-randomized to either continue reference adalimumab or switch to CT-P17 until the end of the study; all patients initially randomized to CT-P17 continued receiving CT-P17. The primary end point was ACR20 (a composite measure defined as improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in 3 of the following 5 criteria: patient global assessment, physician global assessment, functional ability measure, visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein) response rate at week 24; secondary end points were efficacy, pharmacokinetics, safety, and immunogenicity.

A total of 648 eligible patients received CT-P17 (n = 324) or reference adalimumab (n = 324). Baseline characteristics were similar between groups. The ACR20 response rate at week 24 was the same between the CT-P17 and reference adalimumab groups (82.7% for both), with confidence intervals of the treatment difference within the prespecified equivalence margins (European Medicines Agency, ±15%; US Food and Drug Administration, –12% to +15%). Secondary efficacy end points were also similar between groups.

Overall, safety profiles of the 2 groups were similar; 52.2% of patients in the biosimilar group and 56.8% of patients in the reference adalimumab group experienced ≥1 treatment-emergent adverse events (TEAEs); the majority of TEAEs were grade 1/2. The most common TEAEs were injection-site reactions, occurring in 4.9% of patients in the CT-P17 group versus 6.8% in the reference adalimumab group. A total of 26 patients experienced ≥1 treatment-emergent serious adverse events. TEAEs leading to study discontinuation were reported in 5 patients in the CT-P17 group versus 8 patients in the reference adalimumab group.

A lower proportion of patients developed antidrug antibodies (ADAs) at week 24 in the CT-P17 group versus the reference adalimumab (28.7% vs 35.8%; P = .0643). Of these, neutralizing ADAs were developed by 83 (25.6%) CT-P17–treated patients and 103 (31.8%) patients who received reference adalimumab.

This study demonstrated efficacy equivalence between the biosimilar CT-P17 and reference adalimumab over 24 weeks in patients with active, moderate-to-severe RA in terms of ACR20 response rates and other efficacy end points assessed.

Reference
Kay J, et al. ACR 2020. Abstract 800.

Related Items


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: